Loading...

We've got a brand new version of Simply Wall St! Try it out

Rhone Ma Holdings Berhad

KLSE:RHONEMA
Snowflake Description

Adequate balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RHONEMA
KLSE
MYR121M
Market Cap
  1. Home
  2. MY
  3. Pharmaceuticals & Biotech
Company description

Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of animal health products primarily in Malaysia. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
RHONEMA Share Price and Events
7 Day Returns
-3.6%
KLSE:RHONEMA
-2.9%
MY Pharmaceuticals
-0%
MY Market
1 Year Returns
-7.4%
KLSE:RHONEMA
10.8%
MY Pharmaceuticals
-2.5%
MY Market
RHONEMA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rhone Ma Holdings Berhad (RHONEMA) -3.6% -2.2% -5% -7.4% - -
MY Pharmaceuticals -2.9% -1% 7.2% 10.8% 63.6% 70.8%
MY Market -0% -1.8% -0.3% -2.5% -7.4% -8.2%
1 Year Return vs Industry and Market
  • RHONEMA underperformed the Pharmaceuticals industry which returned 10.8% over the past year.
  • RHONEMA underperformed the Market in Malaysia which returned -2.5% over the past year.
Price Volatility
RHONEMA
Industry
5yr Volatility vs Market

Value

 Is Rhone Ma Holdings Berhad undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Rhone Ma Holdings Berhad to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Rhone Ma Holdings Berhad.

KLSE:RHONEMA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in MYR MYR .030000
Payout Ratio Company Filings (2019-09-30) 6597.1%
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year MY Government Bond Rate 3.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KLSE:RHONEMA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year MY Govt Bond Rate 3.4%
Equity Risk Premium S&P Global 7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.685 (1 + (1- 24%) (11.85%))
0.799
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.42% + (0.8 * 6.96%)
8.99%

Discounted Cash Flow Calculation for KLSE:RHONEMA using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Rhone Ma Holdings Berhad is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

KLSE:RHONEMA Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= MYR0.03 / (8.99% - 3.42%)
MYR0.53
KLSE:RHONEMA Discount to Share Price
Calculation Result
Value per share (MYR) From above. MYR0.53
Current discount Discount to share price of MYR0.67
= -1 x (MYR0.67 - MYR0.53) / MYR0.53
-25.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Rhone Ma Holdings Berhad is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rhone Ma Holdings Berhad's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rhone Ma Holdings Berhad's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KLSE:RHONEMA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in MYR MYR0.05
KLSE:RHONEMA Share Price ** KLSE (2019-12-10) in MYR MYR0.67
Malaysia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 13.85x
Malaysia Market PE Ratio Median Figure of 586 Publicly-Listed Companies 14.46x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rhone Ma Holdings Berhad.

KLSE:RHONEMA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KLSE:RHONEMA Share Price ÷ EPS (both in MYR)

= 0.67 ÷ 0.05

13.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rhone Ma Holdings Berhad is overvalued based on earnings compared to the MY Pharmaceuticals industry average.
  • Rhone Ma Holdings Berhad is good value based on earnings compared to the Malaysia market.
Price based on expected Growth
Does Rhone Ma Holdings Berhad's expected growth come at a high price?
Raw Data
KLSE:RHONEMA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 13.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Pharmaceuticals Industry PEG Ratio Median Figure of 169 Publicly-Listed Pharmaceuticals Companies 1.34x
Malaysia Market PEG Ratio Median Figure of 261 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rhone Ma Holdings Berhad, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rhone Ma Holdings Berhad's assets?
Raw Data
KLSE:RHONEMA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in MYR MYR0.58
KLSE:RHONEMA Share Price * KLSE (2019-12-10) in MYR MYR0.67
Malaysia Pharmaceuticals Industry PB Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.22x
Malaysia Market PB Ratio Median Figure of 911 Publicly-Listed Companies 0.76x
KLSE:RHONEMA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KLSE:RHONEMA Share Price ÷ Book Value per Share (both in MYR)

= 0.67 ÷ 0.58

1.16x

* Primary Listing of Rhone Ma Holdings Berhad.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rhone Ma Holdings Berhad is good value based on assets compared to the MY Pharmaceuticals industry average.
X
Value checks
We assess Rhone Ma Holdings Berhad's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Rhone Ma Holdings Berhad has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Rhone Ma Holdings Berhad expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rhone Ma Holdings Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.9%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rhone Ma Holdings Berhad expected to grow at an attractive rate?
  • Unable to compare Rhone Ma Holdings Berhad's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Rhone Ma Holdings Berhad's earnings growth to the Malaysia market average as no estimate data is available.
  • Unable to compare Rhone Ma Holdings Berhad's revenue growth to the Malaysia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KLSE:RHONEMA Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.9%
Asia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 10.4%
Malaysia Market Earnings Growth Rate Market Cap Weighted Average 11%
Malaysia Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KLSE:RHONEMA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in MYR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KLSE:RHONEMA Future Estimates Data
Date (Data in MYR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
KLSE:RHONEMA Past Financials Data
Date (Data in MYR Millions) Revenue Cash Flow Net Income *
2019-09-30 119 3 9
2019-06-30 123 2 9
2019-03-31 123 3 9
2018-12-31 135 7 10
2018-09-30 141 10 11
2018-06-30 145 11 13
2018-03-31 148 13 14
2017-12-31 137 5 14
2017-09-30 133 1 8
2016-12-31 119 7 9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Rhone Ma Holdings Berhad is high growth as no earnings estimate data is available.
  • Unable to determine if Rhone Ma Holdings Berhad is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KLSE:RHONEMA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Rhone Ma Holdings Berhad Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KLSE:RHONEMA Future Estimates Data
Date (Data in MYR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
KLSE:RHONEMA Past Financials Data
Date (Data in MYR Millions) EPS *
2019-09-30 0.05
2019-06-30 0.05
2019-03-31 0.05
2018-12-31 0.06
2018-09-30 0.06
2018-06-30 0.07
2018-03-31 0.08
2017-12-31 0.08
2017-09-30 0.05
2016-12-31 0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rhone Ma Holdings Berhad will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Rhone Ma Holdings Berhad's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Rhone Ma Holdings Berhad's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Rhone Ma Holdings Berhad's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rhone Ma Holdings Berhad has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Rhone Ma Holdings Berhad performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rhone Ma Holdings Berhad's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rhone Ma Holdings Berhad's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Rhone Ma Holdings Berhad's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Rhone Ma Holdings Berhad's 1-year earnings growth is negative, it can't be compared to the MY Pharmaceuticals industry average.
Earnings and Revenue History
Rhone Ma Holdings Berhad's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rhone Ma Holdings Berhad Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KLSE:RHONEMA Past Revenue, Cash Flow and Net Income Data
Date (Data in MYR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 118.80 8.68 24.08
2019-06-30 122.74 8.97 23.66
2019-03-31 122.69 9.06 23.57
2018-12-31 135.24 10.07 23.80
2018-09-30 140.81 11.35 24.41
2018-06-30 144.65 12.55 24.70
2018-03-31 148.46 13.79 23.96
2017-12-31 137.49 13.91 23.72
2017-09-30 132.57 8.49 22.20
2016-12-31 119.20 9.17 19.07
2015-12-31 105.43 12.03 17.20
2014-12-31 91.53 17.58 16.55
2013-12-31 83.72 12.59 17.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Rhone Ma Holdings Berhad has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Rhone Ma Holdings Berhad used its assets more efficiently than the MY Pharmaceuticals industry average last year based on Return on Assets.
  • Rhone Ma Holdings Berhad's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Rhone Ma Holdings Berhad's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rhone Ma Holdings Berhad has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Rhone Ma Holdings Berhad's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rhone Ma Holdings Berhad's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rhone Ma Holdings Berhad is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rhone Ma Holdings Berhad's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rhone Ma Holdings Berhad's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rhone Ma Holdings Berhad Company Filings, last reported 2 months ago.

KLSE:RHONEMA Past Debt and Equity Data
Date (Data in MYR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 105.11 14.36 8.29
2019-06-30 106.75 13.96 11.65
2019-03-31 104.63 13.93 15.65
2018-12-31 104.19 14.44 24.82
2018-09-30 101.91 11.94 29.58
2018-06-30 103.75 12.25 34.04
2018-03-31 101.54 12.64 39.84
2017-12-31 102.43 7.85 34.45
2017-09-30 98.86 3.71 35.67
2016-12-31 95.16 4.81 45.50
2015-12-31 56.93 7.41 14.00
2014-12-31 47.73 3.19 9.95
2013-12-31 50.75 4.93 5.35
  • Rhone Ma Holdings Berhad's level of debt (13.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (8.2% vs 13.6% today).
  • Debt is not well covered by operating cash flow (18.8%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 13.6x coverage).
X
Financial health checks
We assess Rhone Ma Holdings Berhad's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rhone Ma Holdings Berhad has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Rhone Ma Holdings Berhad's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.51%
Current annual income from Rhone Ma Holdings Berhad dividends.
If you bought MYR2,000 of Rhone Ma Holdings Berhad shares you are expected to receive MYR90 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Rhone Ma Holdings Berhad's pays a higher dividend yield than the bottom 25% of dividend payers in Malaysia (1.9%).
  • Rhone Ma Holdings Berhad's dividend is below the markets top 25% of dividend payers in Malaysia (4.8%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KLSE:RHONEMA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Malaysia Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.8%
Malaysia Market Average Dividend Yield Market Cap Weighted Average of 463 Stocks 3.6%
Malaysia Minimum Threshold Dividend Yield 10th Percentile 1.2%
Malaysia Bottom 25% Dividend Yield 25th Percentile 1.9%
Malaysia Top 25% Dividend Yield 75th Percentile 4.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KLSE:RHONEMA Future Dividends Estimate Data
Date (Data in MYR) Dividend per Share (annual) Avg. No. Analysts
KLSE:RHONEMA Past Annualized Dividends Data
Date (Data in MYR) Dividend per share (annual) Avg. Yield (%)
2019-04-18 0.030 4.161
2019-01-17 0.030 4.008
2018-04-26 0.046 5.979
2018-01-15 0.046 5.695
2017-04-27 0.036 3.658
2017-02-21 0.036 4.091

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rhone Ma Holdings Berhad has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Rhone Ma Holdings Berhad has only been paying a dividend for 3 years, and since then dividends per share have fallen.
Current Payout to shareholders
What portion of Rhone Ma Holdings Berhad's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.4x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Rhone Ma Holdings Berhad's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rhone Ma Holdings Berhad afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rhone Ma Holdings Berhad has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Rhone Ma Holdings Berhad's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
I-Ie Lim
COMPENSATION MYR50,000
AGE 48
CEO Bio

Dr. Ban Keong Lim, also known as I-Ie, serves as Group Managing Director of Rhone Ma Holdings Berhad and has been its Director since April 1, 2015. Dr. Lim is responsible for the overall management of Rhone Ma Holdings Berhad's operations, strategic planning and development of its business strategies. Since 2000, he has been the Techno-Commercial Manager of RMM and was subsequently promoted to General Manager in 2010 and assumed the role of Managing Director in 2013. He began his career as Technical Sales Executive at Pahang Pharmacy Sdn Bhd in 1997 where he was responsible for providing veterinary services and promoting veterinary products to swine and poultry farms. Dr. Lim left Pahang Pharmacy Sdn Bhd in 1998 and joined Rhone-Poulenc Malaysia Sdn Bhd (which was subsequently known as Rhodia Malaysia Sdn Bhd in 1998) as a Techno-Commercial Executive in the animal health division. He was in charge of the product portfolio covering veterinary pharmaceutical and biological products during his tenure with Rhodia Malaysia Sdn Bhd. Subsequently in 2000, he left Rhodia Malaysia Sdn Bhd and joined RMM which acquired the animal health division of Rhodia Malaysia Sdn Bhd. He is also a veterinary surgeon registered with the Malaysian Veterinary Council since 1997 and a member of the Veterinary Association Malaysia since 1998. He graduated from Universiti Putra Malaysia with a Doctor of Veterinary Medicine in 1997.

CEO Compensation
  • I-Ie's compensation has been consistent with company performance over the past year, both up more than 20%.
  • I-Ie's remuneration is lower than average for companies of similar size in Malaysia.
Management Team Tenure

Average tenure and age of the Rhone Ma Holdings Berhad management team in years:

5.9
Average Tenure
53.5
Average Age
  • The average tenure for the Rhone Ma Holdings Berhad management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

I-Ie Lim

TITLE
Group MD & Director
COMPENSATION
MYR50K
AGE
48

Lai Yip

TITLE
Group Marketing & Technical Director and Executive Director
COMPENSATION
MYR50K
AGE
57

Kam Weng Foong

TITLE
Group Sales Director & Executive Director
COMPENSATION
MYR50K
AGE
59

Calvin Chan

TITLE
Group Finance Director
AGE
50
TENURE
5.9 yrs

Wee Goh

TITLE
Group General Manager of Operations
AGE
61
TENURE
5.9 yrs

Hang Lim

TITLE
Head of Business Development
AGE
40
TENURE
1.9 yrs

Kean Lim

TITLE
Head of Internal Audit

Samantha Tai

TITLE
Company Secretary

Ai Tan

TITLE
Company Secretary
Board of Directors Tenure

Average tenure and age of the Rhone Ma Holdings Berhad board of directors in years:

4.7
Average Tenure
59
Average Age
  • The tenure for the Rhone Ma Holdings Berhad board of directors is about average.
Board of Directors

Hamzah Bin Mohd Salleh

TITLE
Independent Non-Executive Chairman
COMPENSATION
MYR65K
AGE
71

I-Ie Lim

TITLE
Group MD & Director
COMPENSATION
MYR50K
AGE
48
TENURE
4.7 yrs

Lai Yip

TITLE
Group Marketing & Technical Director and Executive Director
COMPENSATION
MYR50K
AGE
57
TENURE
4.7 yrs

Kam Weng Foong

TITLE
Group Sales Director & Executive Director
COMPENSATION
MYR50K
AGE
59
TENURE
4.7 yrs

Thiagaraj Jeyaratnam

TITLE
Senior Independent Non-Executive Director
COMPENSATION
MYR56K
AGE
73

Rahanawati Binti Ali Dawam

TITLE
Independent Non-Executive Director
COMPENSATION
MYR56K
AGE
67
TENURE
4.7 yrs

Chee Teoh

TITLE
Independent Non-Executive Director
COMPENSATION
MYR55K
AGE
48
TENURE
4.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (MYR) Value (MYR)
X
Management checks
We assess Rhone Ma Holdings Berhad's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rhone Ma Holdings Berhad has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of animal health products primarily in Malaysia. The company operates through Animal Health Products, Food Ingredients, and Others segments. Its products include avian, swine, feline, canine, and equine vaccines; pharmaceuticals, including antimicrobials, anticoccidials, health supplements, non-antimicrobials, disinfectants, etc.; and feed additives, such as mycotoxin binders, antifungal products, premixes, mold inhibitors, nutritional supplements, supplements for gut health and performance growth enhancement, anthelmintic products, etc. The company also provides diagnostic laboratory analysis services to veterinary, agriculture, and food industries, as well as offers management services; and veterinary advisory services, as well as undertakes research and development activities related to animal health, food safety, and agriculture. In addition, the company provides tests and diagnostics services for human healthcare; conducts research and development in biotechnology; and distributes human healthcare and related products. Further, it distributes and supplies food ingredients to bakeries and food manufacturers, as well as producers of confectionaries, ice creams, sauces, and snakes. Rhone Ma Holdings Berhad was founded in 2000 and is based in Petaling Jaya, Malaysia. Rhone Ma Holdings Berhad is a subsidiary of Blue Advantage Sdn. Bhd.

Details
Name: Rhone Ma Holdings Berhad
RHONEMA
Exchange: KLSE
Founded: 2000
MYR121,429,000
182,600,000
Website: http://www.rhonema.com
Address: Rhone Ma Holdings Berhad
Lot 18A & 18B,
Jalan 241,
Petaling Jaya,
Selangor, 46100,
Malaysia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KLSE RHONEMA Ordinary Shares Bursa Malaysia MY MYR 19. Dec 2016
Number of employees
Current staff
Staff numbers
0
Rhone Ma Holdings Berhad employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/10 16:30
End of day share price update: 2019/12/10 00:00
Last estimates confirmation: 2017/02/21
Last earnings filing: 2019/11/20
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.